Overview

Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The present trial is a randomized, placebo-controlled study evaluating 3 different doses of PXT3003 in patients with CMT1A disease.
Phase:
Phase 2
Details
Lead Sponsor:
Pharnext SA